Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL411563 | 0.98 | TBXAS1 (0.59) | HMOX2TBXAS1 | |
| SCHEMBL8804388 | 0.91 | TBXAS1 (0.59) | HMOX2TBXAS1 | |
| Hydrochloric Acid SCHEMBL9996084 | 0.90 | TBXAS1 (0.61) | HMOX2TBXAS1 | |
| SCHEMBL10247518 | 0.87 | CYP19A1 (0.59) | TBXAS1 | |
| SCHEMBL11240853 | 0.87 | TBXAS1 (0.57) | TBXAS1 | |
| SCHEMBL10247382 | 0.87 | CYP11B1 (0.58) | HMOX2TBXAS1 | |
| SCHEMBL410653 | 0.85 | CYP19A1 (0.58) | TBXAS1 | |
| SCHEMBL406793 | 0.85 | TBXAS1 (0.59) | TBXAS1 | |
| SCHEMBL11269558 | 0.85 | PLA2G4A (0.58) | HMOX2TBXAS1 | |
| Hydrochloric Acid SCHEMBL9996061 | 0.85 | TBXAS1 (0.58) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-8513294-B2 | Substituted imidazole derivatives and methods of use thereof for treating cancer | OSTA BIOTECHNOLOGIES (CA) | 2013-08-20 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
| EP-0492474-B1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX INC (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5158949-A | 1,3-DIOXOLANE DERIVATIVES AS CHOLESTEROL-LOWERING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0492474-A1 | 1,3-Dioxolane derivatives as cholesterol-lowering agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4375474-A | BACTERICIDES, FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4359475-A | SPERMICIDES, MICROBIOCIDES OR ANTICONVULSANTS | SYNTEX (U.S.A.) INC. (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0064244-A1 | Spermicidal 1-bis(arylalkyl)alkylimidazoles | SYNTEX (U.S.A.) INC. (US) | 1982-11-10 | — | — | EP | disclosed |
| EP-0049565-A2 | Derivatives of substituted N-alkylimidazoles, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | HMOX2 3/4885TBXAS1 469/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX2 2/4885TBXAS1 1071/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX2 2/4885TBXAS1 1071/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | HMOX2 2/4885TBXAS1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.